Tag: Viral Genetics and Evolution

797 Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2 negative metastatic breast cancer

Background Combination of eribulin and immune checkpoint inhibitor (ICI) showed durable response for HER-2 negative metastatic breast cancer (MBC) patients, but PD-L1 expression was not associated with efficacy. Here, we report the whole exome sequencing (WES) and whole transcriptome sequencing (WTS) analysis of pretreatment tumor tissues from the phase II clinical trial of the eribulin… Continue reading 797 Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2 negative metastatic breast cancer

557 Chronicity of exposure and ensuing resistance to platinum chemotherapy sensitizes homologous recombination-deficient pancreatic ductal adenocarcinoma to immune checkpoint blockade

AI SummaryPancreatic cancer patients with deficiencies in homologous recombination are initially treated with platinum-based chemotherapy but can become resistant. Researchers found that patients who developed resistance to platinum chemotherapy responded well to immune checkpoint blockade (ICB) treatment. In a preclinical study, mice with platinum-resistant pancreatic cancer cells also showed reduced tumor growth when treated with… Continue reading 557 Chronicity of exposure and ensuing resistance to platinum chemotherapy sensitizes homologous recombination-deficient pancreatic ductal adenocarcinoma to immune checkpoint blockade

418 The development of ‘off-the-shelf manufacturing strategies of iPSC-based gamma-delta T cells

Background Gamma-delta () T cells are depleted during cancer progression resulting in the progressive loss of anti-cancer activity. Elevated numbers of T cells are associated with greater survival outcomes in both hematopoietic and solid malignancies. Induced pluripotent stem cell (iPSC) derived T cells could address the therapeutic challenges of multiple allogeneic T cell infusions as… Continue reading 418 The development of ‘off-the-shelf manufacturing strategies of iPSC-based gamma-delta T cells

185 Global and local copy number aberration signatures as prognostic and immunotherapeutic predictors

AI SummaryCopy number aberrations (CNAs) can be used as an alternative approach to predict responses to immune checkpoint inhibitors in lung cancer patients. The study found that a higher total copy number burden (TCB) was associated with poorer overall survival in lung cancer patients. Homologous recombination deficiency (HRD) score was significantly associated with unfavorable survival… Continue reading 185 Global and local copy number aberration signatures as prognostic and immunotherapeutic predictors

75 The mutational landscape defines the proteome and spatial organization of tumor, stroma, and immune cells in ovarian cancer

Background High-grade serous ovarian cancer (HGSOC) is highly aggressive and lethal, with clinical challenges to both diagnosis and treatment. The genomic instability of HGSOC, further complicated by homologous recombination deficiency (HRD), leads to heterogeneity in the HGSOC tumors and patient response to treatment. We have previously profiled the complete proteome of tumors from 32 HGSOC… Continue reading 75 The mutational landscape defines the proteome and spatial organization of tumor, stroma, and immune cells in ovarian cancer

Misadjustment of post-trial life-prolonging therapies in the second interim analysis of the MAGNITUDE trial

Dear Editor, Chi et al.1 have updated the second interim analysis of the MAGNITUDE trial assessing niraparib plus abiraterone acetate with prednisone (AAP) for patients with metastatic castration-resistant prostate cancer (mCRPC). Although niraparib plus AAP as the first-line treatment significantly prolonged radiographic progression-free survival, it showed no benefit on overall survival (OS) of patients with… Continue reading Misadjustment of post-trial life-prolonging therapies in the second interim analysis of the MAGNITUDE trial

FDA Approvals in Oncology: July-September 2023

With the approval of new anticancer therapeutics, more treatment options become available for patients. Some therapies are new to the market, while some may have already been approved for other indications; some molecules are first in class, directed against a previously untargeted pathway or acting through a new mechanism, while others may be improved versions… Continue reading FDA Approvals in Oncology: July-September 2023